Wang Xingyuan, Chen Zeyu, Qiu Shi, Cao Dehong, Jin Kun, Li Jin, Chen Bo, Huang Yin, Bao Yige, Liu Liangren, Wei Qiang
Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, People's Republic of China.
West China School of Medicine, Sichuan University, Chengdu, People's Republic of China.
Cancer Manag Res. 2020 Jun 23;12:4883-4888. doi: 10.2147/CMAR.S236618. eCollection 2020.
To study the effect of cryptorchidism on clinical stage (CS) of testicular seminoma (TS).
In the Surveillance Epidemiology and End Results (SEER) database (2006-2016), people with TS were enrolled in our research. Multivariable logistic regression models were constructed to compare the impact of cryptorchidism on CS.
This research was based on the registry information of 12,991 TS patients. All patients with a median age of 36 (13-107) years were pathologically diagnosed with orchiectomy or needle biopsy specimens. Patients with CS I, II, and III TS accounted for 70.68% (n = 9182), 8.30% (n = 1078), and 5.75% (n = 747) of all patients, respectively; still there were 15.27% (n = 1984) of patients whose CS could not be identified or was not available. Among all included patients, 43.45% (n = 5644) of them had normal testis, 2.93% (n = 272) had cryptorchidism, and the primary site of 54.46% (n = 7075) of patients' testis was unavailable. According to our study, patients with cryptorchidism were more likely to suffer advanced CS [OR=1.14, 95% CI (1.01-1.28), p=0.0407]. Furthermore, this effect became more remarkable after adjusting for other factors including age, region, marital status, race, year of diagnosis and laterality [OR=1.23, 95% CI (1.13-1.32), p<0.0001].
According to this study, TS patients with cryptorchidism would be at a higher risk of suffering advanced cancer than patients with normal testis. It demonstrates that surgical correction for cryptorchidism should be timely, and specific management should be conducted on this kind of TS patients.
研究隐睾症对睾丸精原细胞瘤(TS)临床分期(CS)的影响。
在监测、流行病学和最终结果(SEER)数据库(2006 - 2016年)中,纳入患有TS的人群。构建多变量逻辑回归模型,以比较隐睾症对CS的影响。
本研究基于12991例TS患者的登记信息。所有患者的中位年龄为36(13 - 107)岁,均经病理诊断,取材于睾丸切除术或针吸活检标本。CS I、II和III期TS患者分别占所有患者的70.68%(n = 9182)、8.30%(n = 1078)和5.75%(n = 747);仍有15.27%(n = 1984)的患者CS无法确定或未提供。在所有纳入患者中,43.45%(n = 5644)睾丸正常,2.93%(n = 272)患有隐睾症,54.46%(n = 7075)患者的睾丸原发部位不详。根据我们的研究,患有隐睾症的患者更易出现晚期CS [比值比(OR)=1.14,95%置信区间(CI)(1.01 - 1.28),p = 0.0407]。此外,在调整年龄、地区、婚姻状况、种族、诊断年份和患侧性等其他因素后,这种影响更为显著[OR = 1.23,95% CI(1.13 - 1.32),p < 0.0001]。
根据本研究,患有隐睾症的TS患者比睾丸正常的患者患晚期癌症的风险更高。这表明应及时对隐睾症进行手术矫正,并对这类TS患者进行特殊管理。